Dr. Murphy is co-Vice Chair of A5230. He played an integral role in development of the overall concept and assisted in the writing of the protocol and development of the budget. He will participate in all team conference calls during the protocol development and once the protocol is approved and implemented by the ACTG sites. He will assist the protocol chair in operations of the protocol. Along with the co-Vice Chair, he will assist with all administrative, laboratory and operational aspects of the study. In the invent the protocol chair is absent, he will temporarily perform the functions of the chair as needed. Dr. Murphy will liaison with the Hepatitis TSG, Data Management Committee and Adult Executive Committee regarding any issues with the study relevant to those leadership committees.
|Effective start/end date||1/1/14 → 11/30/18|
- Brigham and Womens Hospital (110236 A5320//5UM1AI068636-12)
- National Institute of Allergy and Infectious Diseases (110236 A5320//5UM1AI068636-12)